NCT07439991 Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery
| NCT ID | NCT07439991 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Hospital of Jilin University |
| Condition | Lung Cancer (Diagnosis) |
| Study Type | OBSERVATIONAL |
| Enrollment | 900 participants |
| Start Date | 2024-11-01 |
| Primary Completion | 2029-11-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this observational study is to learn about the risk factors and prediction of postoperative venous thromboembolism (VTE) in patients undergoing lung cancer surgery. The main question it aims to answer is: Which clinical, surgical, and laboratory factors are associated with the development of postoperative deep vein thrombosis (DVT) in lung cancer surgery patients, and can machine learning models accurately predict individual risk? Participants undergoing lung cancer surgery will be prospectively followed for 30 days after surgery. Perioperative clinical data, laboratory results, and imaging findings will be collected to identify VTE risk factors and to develop a predictive model.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years 2. Patients undergoing surgical resection for lung cancer 3. Postoperative hospital stay ≥ 48 hours 4. Availability of perioperative clinical, laboratory, and imaging data 5. Willingness to provide informed consent and participate in 30-day follow-up Exclusion Criteria: 1. Pre-existing deep vein thrombosis (DVT) or pulmonary embolism (PE) before surgery 2. Preoperative or ongoing anticoagulation therapy for ≥ 2 weeks 3. Severe coagulation disorders or bleeding diseases 4. Severe hepatic, renal, or hematologic dysfunction, or uncontrolled systemic infection 5. Concurrent major organ surgery (e.g., cardiac, liver surgery) 6. Pregnancy or lactation 7. Incomplete postoperative follow-up data
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.